4.6 Article

Baby NINJA (Nephrotoxic Injury Negated by Just-in-Time Action): Reduction of Nephrotoxic Medication-Associated Acute Kidney Injury in the Neonatal Intensive Care Unit

Journal

JOURNAL OF PEDIATRICS
Volume 215, Issue -, Pages 223-+

Publisher

MOSBY-ELSEVIER
DOI: 10.1016/j.jpeds.2019.08.046

Keywords

-

Categories

Funding

  1. Pediatric and Infant Center for Acute Nephrology (PICAN)
  2. Department of Pediatrics at the University of Alabama at Birmingham - Children's of Alabama Hospital
  3. UAB's Center for Clinical and Translational Sciences (CCTS) [UL1TR001417]
  4. Casey Lee Ball Foundation
  5. Agency for Healthcare Research and Quality [1R18HS023763-01]
  6. Acute Kidney Injury (AKI) Foundation (Cincinnati, OH)
  7. Octapharma AG (Switzerland)
  8. Baxter
  9. National Institutes of Health-National Institutes of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK) [R01 DK103608]
  10. Medtronic
  11. MediBeacon
  12. AM Pharma, La Jolla Pharmaceutical ExThera
  13. CHF Solutions
  14. Baxter and Bioporto

Ask authors/readers for more resources

Objective(s) To test if acute kidney injury (AKI) is preventable in patients in the neonatal intensive care unit and if infants at high-risk of nephrotoxic medication-induced AKI can be identified using a systematic surveillance program previously used in the pediatric non-intensive care unit setting. Study design Quality improvement project that occurred between March 2015 and September 2017 in a single center, level IV neonatal intensive care unit. Infants were screened for high-risk nephrotoxic medication exposure (>= 3 nephrotoxic medication within 24 hours or >= 4 calendar days of an intravenous [IV] aminoglycoside). If infants met criteria, a daily serum creatinine (SCr) was obtained until 2 days after end of exposure or end of AKI, whichever occurred last. The study was divided into 3 eras: pre-Nephrotoxic Injury Negated by Just-in-time Action (NINJA), initiation, and sustainability. Differences for 5 metrics across 3 eras were compared: SCr surveillance, high nephrotoxic medication exposure rate (per 1000 patient-days), AKI rate (per 1000 patient-days), nephrotoxin-AKI percentage, and AKI intensity (number of AKI days per 100 susceptible patient-days). Results Comparing the initiation with sustainability era, there was a reduction in high nephrotoxic medication exposures from 16.4 to 9.6 per 1000 patient-days (P = .03), reduction in percentage of nephrotoxic medication-AKI from 30.9% to 11.0% (P < .001), and reduction in AKI intensity from 9.1 to 2.9 per 100 susceptible patient-days (P < .001) while maintaining a high SCr surveillance rate. This prevented 100 AKI episodes during the 18-month sustainability era. Conclusion(s) A systematic surveillance program to identify high-risk infants can prevent nephrotoxic-induced AKI and has the potential to prevent short and long-term consequences of AKI in critically ill infants.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available